New cocktail of drugs takes on tough pancreatic cancer

NCT ID NCT07488884

Not yet recruiting Disease control Sponsor: ImmunityBio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether adding three new drugs (nogapendekin alfa inbakicept, sotevtamab, and zabadinostat) to standard chemotherapy can safely shrink pancreatic tumors that are hard to remove. About 30 adults with borderline resectable or locally advanced pancreatic cancer will receive the combination before surgery, then continue immunotherapy afterward. The main goal is to check for side effects and see if the treatment helps control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nogapendekin alfa inbakicept, sotevtamab, zabadinostat, gemcitabine, nab-paclitaxel
What this could lead to: If successful, this could point toward a more effective treatment approach for pancreatic cancer that is hard to remove with surgery alone.
What could go wrong: This is a very early phase 1 trial with only 30 people, focused on safety. The drug combination may cause serious side effects and may not shrink tumors enough to allow surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER PANCREATIC CANCER RESECTABLE

More trials for these conditions

Other studies related to the condition(s) this trial covers.